DeFilipp, Z., Duarte, R.F., Snowden, J.A. et al. (34 more authors) (2016) Metabolic Syndrome and Cardiovascular Disease after Hematopoietic Cell Transplantation: Screening and Preventive Practice Recommendations from the CIBMTR and EBMT. Biology of Blood and Marrow Transplantation, 22 (8). pp. 1493-1503. ISSN 1083-8791
Abstract
Metabolic syndrome (MetS) is a constellation of cardiovascular risk factors that increases the risk of cardiovascular disease, diabetes mellitus, and all-cause mortality. Long-term survivors of hematopoietic cell transplantation (HCT) have a substantial risk of developing MetS and cardiovascular disease, with an estimated prevalence of MetS of 31% to 49% among HCT recipients. Although MetS has not yet been proven to impact cardiovascular risk after HCT, an understanding of the incidence and risk factors for MetS in HCT recipients can provide the foundation to evaluate screening guidelines and develop interventions that may mitigate cardiovascular-related mortality. A working group was established through the Center for International Blood and Marrow Transplant Research and the European Group for Blood and Marrow Transplantation with the goal to review literature and recommend practices appropriate to HCT recipients. Here we deliver consensus recommendations to help clinicians provide screening and preventive care for MetS and cardiovascular disease among HCT recipients. All HCT survivors should be advised of the risks of MetS and encouraged to undergo recommended screening based on their predisposition and ongoing risk factors.
Metadata
Item Type: | Article |
---|---|
Authors/Creators: |
|
Copyright, Publisher and Additional Information: | © 2016 Elsevier. This is an author produced version of a paper subsequently published in Biology of Blood and Marrow Transplantation. Uploaded in accordance with the publisher's self-archiving policy. Article available under the terms of the CC-BY-NC-ND licence (https://creativecommons.org/licenses/by-nc-nd/4.0/) |
Keywords: | Metabolic syndrome; Cardiovascular disease; Hematopoietic cell transplantation; Survivorship; Late effects |
Dates: |
|
Institution: | The University of Sheffield |
Academic Units: | The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > The Medical School (Sheffield) > Division of Genomic Medicine (Sheffield) > Department of Oncology and Metabolism (Sheffield) The University of Sheffield > Sheffield Teaching Hospitals |
Depositing User: | Symplectic Sheffield |
Date Deposited: | 15 Aug 2016 12:26 |
Last Modified: | 05 Nov 2017 21:39 |
Published Version: | http://dx.doi.org/10.1016/j.bbmt.2016.05.007 |
Status: | Published |
Publisher: | Elsevier |
Refereed: | Yes |
Identification Number: | 10.1016/j.bbmt.2016.05.007 |
Open Archives Initiative ID (OAI ID): | oai:eprints.whiterose.ac.uk:103719 |
Downloads
Filename: Metabolic.pdf
Licence: CC-BY-NC-ND 4.0
Filename: Table01.pdf
Licence: CC-BY-NC-ND 4.0
Filename: Table02.pdf
Licence: CC-BY-NC-ND 4.0
Filename: Table03.pdf
Licence: CC-BY-NC-ND 4.0